Chang H, Tsai C, Hsu C, Tai T, Cheng M, Chuang Y
Nat Metab. 2025; .
PMID: 40045118
DOI: 10.1038/s42255-025-01245-6.
Sun L, Li X, Xu F, Chen Y, Li X, Yang Z
Nat Immunol. 2025; .
PMID: 40045031
DOI: 10.1038/s41590-025-02100-2.
Wang X, Hong Y, Zou J, Zhu B, Jiang C, Lu L
Biomark Res. 2025; 13(1):22.
PMID: 39876010
PMC: 11776340.
DOI: 10.1186/s40364-025-00733-x.
Zhao Z, Wang D, Sheng X, Li S, Liu T, Chang M
Front Immunol. 2025; 15:1429855.
PMID: 39872530
PMC: 11769954.
DOI: 10.3389/fimmu.2024.1429855.
Jafri Z, Li Y, Zhang J, OMeara C, Khachigian L
Int J Mol Sci. 2025; 26(2).
PMID: 39859271
PMC: 11766113.
DOI: 10.3390/ijms26020555.
TRIM28 is an essential regulator of three-dimensional chromatin state underpinning CD8 T cell activation.
Wei K, Li R, Zhao X, Xie B, Xie T, Sun Q
Nat Commun. 2025; 16(1):750.
PMID: 39820353
PMC: 11739657.
DOI: 10.1038/s41467-025-56029-z.
The crosstalk between senescence, tumor, and immunity: molecular mechanism and therapeutic opportunities.
Wang Z, Chen C, Ai J, Gao Y, Wang L, Xia S
MedComm (2020). 2025; 6(1):e70048.
PMID: 39811803
PMC: 11731108.
DOI: 10.1002/mco2.70048.
Development and validation of a prognostic prediction model for endometrial cancer based on CD8+ T cell infiltration-related genes.
Chen C, Pei L, Ren W, Sun J
Medicine (Baltimore). 2024; 103(49):e40820.
PMID: 39654198
PMC: 11630932.
DOI: 10.1097/MD.0000000000040820.
JunB is required for CD8+ T cell responses to acute infections.
Sarkar S, Taira N, Hsieh T, Chien H, Hirota M, Koizumi S
Int Immunol. 2024; 37(4):203-220.
PMID: 39425978
PMC: 11884676.
DOI: 10.1093/intimm/dxae063.
Transcriptional rewiring in CD8 T cells: implications for CAR-T cell therapy against solid tumours.
Srinivasan S, Armitage J, Nilsson J, Waithman J
Front Immunol. 2024; 15:1412731.
PMID: 39399500
PMC: 11466849.
DOI: 10.3389/fimmu.2024.1412731.
Molecular Signatures of CB-6644 Inhibition of the RUVBL1/2 Complex in Multiple Myeloma.
Yi W, Dziadowicz S, Mangano R, Wang L, McBee J, Frisch S
Int J Mol Sci. 2024; 25(16).
PMID: 39201707
PMC: 11354775.
DOI: 10.3390/ijms25169022.
NaCl enhances CD8 T cell effector functions in cancer immunotherapy.
Scirgolea C, Sottile R, De Luca M, Susana A, Carnevale S, Puccio S
Nat Immunol. 2024; 25(10):1845-1857.
PMID: 39198631
DOI: 10.1038/s41590-024-01923-9.
Autocrine VEGF-B signaling maintains lipid synthesis and mitochondrial fitness to support T cell immune responses.
He J, Chen Y, Ding H, Zhou J, Xing Z, Yang X
J Clin Invest. 2024; 134(16).
PMID: 39145452
PMC: 11324299.
DOI: 10.1172/JCI176586.
Enhancing the Efficacy of CAR-T Cell Therapy: A Comprehensive Exploration of Cellular Strategies and Molecular Dynamics.
Baysal M, Chakraborty A, Tsimberidou A
J Cancer Immunol (Wilmington). 2024; 6(1):20-28.
PMID: 39119270
PMC: 11308461.
DOI: 10.33696/cancerimmunol.6.080.
Systematic Analysis of Human Colorectal Cancer scRNA-seq Revealed Limited Pro-tumoral IL-17 Production Potential in Gamma Delta T Cells.
Ran R, Trapecar M, Brubaker D
bioRxiv. 2024; .
PMID: 39071278
PMC: 11275756.
DOI: 10.1101/2024.07.18.604156.
Dynamic Foxp3-chromatin interaction controls tunable Treg cell function.
He M, Zong X, Xu B, Qi W, Huang W, Djekidel M
J Exp Med. 2024; 221(9).
PMID: 38935023
PMC: 11211070.
DOI: 10.1084/jem.20232068.
BATF promotes tumor progression and association with FDG PET-derived parameters in colorectal cancer.
Lu X, Liu J, Feng L, Huang Y, Xu Y, Li C
J Transl Med. 2024; 22(1):558.
PMID: 38862971
PMC: 11165778.
DOI: 10.1186/s12967-024-05367-5.
Dysregulation of CD4 and CD8 resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis.
He J, Kim Y, Mennillo E, Rusu I, Bain J, Rao A
J Immunother Cancer. 2024; 12(4).
PMID: 38642938
PMC: 11033653.
DOI: 10.1136/jitc-2023-008628.
TIM-3 CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies.
Minnie S, Waltner O, Zhang P, Takahashi S, Nemychenkov N, Ensbey K
Sci Immunol. 2024; 9(94):eadg1094.
PMID: 38640253
PMC: 11093588.
DOI: 10.1126/sciimmunol.adg1094.
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies.
Xiang M, Li H, Zhan Y, Ma D, Gao Q, Fang Y
Mol Cancer. 2024; 23(1):73.
PMID: 38581063
PMC: 10996278.
DOI: 10.1186/s12943-024-01987-z.